Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.96M | -17.48M | -14.78M | -14.78M | -12.44M |
| Total Depreciation and Amortization | 15.00K | 15.00K | 13.00K | 13.00K | 14.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.91M | 2.10M | 1.16M | 1.16M | 1.45M |
| Change in Net Operating Assets | -12.00M | -1.86M | -140.00K | -140.00K | 2.94M |
| Cash from Operations | -30.03M | -17.22M | -13.75M | -13.75M | -8.04M |
| Capital Expenditure | -40.00K | -8.00K | -11.50K | -11.50K | -436.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 31.00K | 31.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -40.00K | -8.00K | 19.50K | 19.50K | -436.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 333.54M | 733.50K | 733.50K | 0.00 |
| Repurchase of Common Stock | -975.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 194.70M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 596.00K | -298.00K | -298.00K | -- |
| Cash from Financing | -975.00K | 334.14M | 435.50K | 435.50K | 194.70M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.05M | 316.90M | -13.29M | -13.29M | 186.23M |